2011 Mar. 31st License Agreement of the Transdermal Formulation containing NF-κB Decoy Oligonucleotide Mar. 24th License Agreement for Topical Patch containing etodolac 2010 Jul. 15th Start of Phase III Clinical Trial for MRX-7EAT Apr. 9th The LOI with AnGes MG Inc. on the Transdermal Formulation containing NF-κB Decoy Oligonucleotide 2009 Oct. 1st Establishmenet of a new joint venture campany Aug. 20th “Development of a new cancer pain relief patch to apply the ionic liquid technology” was passed by NEDO (New Energy and Industrial Technology Development Organization) as its innovation advancement project. May. 26th Etodolac Patch (MRX-7EAT) became available for Phase I clinical trial in U.S. 2007 Aug. 2nd Our consortium R&D project was adopted by Ministry of Economy, Trade and Industry as " Consortium R&D projects for regional revitalization in 2007" Oct. 10th Launch Medcaine Oral Jelly 2% 2005 Aug. 22nd Launch Iodocoat Ointment 0.9%